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Despite rapid technical progress and demonstrable effectiveness for some types of diagnosis and therapy, much remains to be learned
about clinical genome and exome sequencing (CGES) and its role within the practice of medicine. The Clinical Sequencing Exploratory
Research (CSER) consortium includes 18 extramural research projects, one National Human Genome Research Institute (NHGRI) intra-
mural project, and a coordinating center funded by the NHGRI and National Cancer Institute. The consortium is exploring analytic and
clinical validity and utility, as well as the ethical, legal, and social implications of sequencing via multidisciplinary approaches; it
has thus far recruited 5,577 participants across a spectrum of symptomatic and healthy children and adults by utilizing both
germline and cancer sequencing. The CSER consortium is analyzing data and creating publically available procedures and tools related
to participant preferences and consent, variant classification, disclosure and management of primary and secondary findings, health
outcomes, and integration with electronic health records. Future research directions will refine measures of clinical utility of CGES in
both germline and somatic testing, evaluate the use of CGES for screening in healthy individuals, explore the penetrance of pathogenic
variants through extensive phenotyping, reduce discordances in public databases of genes and variants, examine social and ethnic dis-
parities in the provision of genomics services, explore regulatory issues, and estimate the value and downstream costs of sequencing. The
CSER consortium has established a shared community of research sites by using diverse approaches to pursue the evidence-based devel-
opment of best practices in genomic medicine.Introduction
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and the CSER Consortiumgenerating evidence to address key challenges in applying
sequencing to the clinical care of individuals.4,5 These
challenges span a range of issues surrounding the genera-
tion, analysis, and interpretation of CGES data, as well as
the translation of these data for the referring physician,
communication to the participant and families, and exam-
ination of the clinical utility and broader ethical, legal, and
social implications (ELSIs) of utilizing genomic data in the
clinic.
Grant applications in response to this RFA employed a
three-project structure. Project 1 addressed ‘‘one or more
areas of medical investigation (i.e., disease or therapeutic
approach) or a specific approach to the use of genotype-
phenotype data within a clinical context (e.g., risk predic-
tion modeling or cancer mutation profiling).’’ Project 2
addressed ‘‘the development of methods to analyze
genomic sequence data for clinically actionable variants,
as well as parsing these data into manageable components
to translate the findings into formats that eased interpreta-
tion of the findings by the clinician.’’ Project 3 ‘‘in-
vestigated how patients understand, react to, and use
individual genomic results when they are offered and re-
turned. [and] investigate[d] the experiences of clinicians
regarding the return of results.’’ Nine sites were funded by
the NIH cooperative agreement or U-award mechanism.
In addition, the NHGRI intramural ClinSeq study joined
the CSER consortium as a tenth site in 2013. These sites,
including ClinSeq, are collectively described as the
U-award sites for convenience throughout the rest of this
paper.
In 2013, the CSER consortium was expanded to incor-
porate a pre-existing consortium (formerly known as the
ELSI Return of Results Consortium) that included nine
previously awarded projects relating to the return of
research results and management of secondary findings
(also called incidental findings) in both research and clin-
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research grant or R-award mechanism and are collec-
tively termed R-award sites in this paper. The consolida-
tion of these projects under the CSER consortium
umbrella has fostered intensive interactions among a
diverse collection of clinicians, genomic researchers, so-
cial scientists, biomedical informaticians, bioethicists,
and legal scholars. A CSER coordinating center8 was
funded in 2013 to facilitate collaborative efforts among
the CSER investigators and to broadly disseminate infor-
mation from the CSER consortium to the biomedical
research community. Consortium investigators have
collaborated to explore distinct but complementary ap-
proaches to utilizing CGES data in the practice of medi-
cine. This report provides a high-level overview of the
consortium, its accomplishments to date, and the com-
munity resources that have been generated. This report
summarizes major steps that the CSER consortium has
taken to improve the future of health care by beginning
to develop clinical sequencing best practices and deter-
mining the effect of this technology on participants, pro-
viders, and the global health-care system. It also reviews
steps that can be taken to further improve the clinical im-
plementation of this developing technology and guide
future health-care policies.Overview of the CSER Consortium
The organization of the consortium and description of the
sites are depicted in Figure 1 and Table 1. Four of the pro-
jects are focused solely on participants diagnosed with can-
cer or at an increased risk of cancer, whereas the remainder
focus on participants with othermedical conditions or self-
reported healthy participants seen in primary care. Across
the projects, there are adult and/or pediatric participant
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Figure 1. Schematic of the Structure of
the CSER Consortium
Grants funded under RFA-HG-11-003 and
RFA- HG-11-004 have ended, but the inves-
tigators on those grants continue to partic-
ipate in consortium activities. Along with
ELSI investigators on the U-awards, they
meet regularly to discuss ELSI issues rele-
vant to CSER. Note: this figure was updated
for the purposes of this publication and is
reproduced with permission from the
CSER consortium; it is now available on
the CSER website (see Web Resources).sequencing (Table 1). The R-awards have considerable syn-
ergy with the ELSI components (project 3) of the U-award
(Table 2). The ELSI projects utilize quantitative and qualita-
tive empirical approaches, along with normative and legal
analyses, in most cases by employing multiple methods.
There are also nine cross-project, collaborative working
groups (Table 3). Details of the U-award, the R-award, the
consortium-wide working groups, and additional pub-
lished and preliminary data are provided in the Supple-
mental Data.
As shown in Figure 2, the U-award sites collectively
have thus far recruited 5,577 participants to date (4,429
adults and 1,148 children) and anticipate the eventual
recruitment of approximately 7,101 participants, 6,210 of
whom are subjects undergoing CGES, when enrollment
at each of the sites is completed. Table 4 shows a further
breakdown of the indications for sequencing and the diag-
nostic yields obtained.
Whereas each U-award project conforms to the tripar-
tite requirements of the original RFA, the clinical studies
include observational or interventional designs (including
randomized trials). Some projects sequence only pro-
bands, whereas others sequence parent-child trios. In
addition to performing exome and genome sequencing,
one cancer project performs tumor RNA sequencing.
Whereas some projects return results only from a list of
known disease-associated genes, others return variants
from any gene that has a potentially valid association.
This variation in approach has resulted in differences
among the studies in the diagnostic yield, defined as the
percentage of participants with at least one plausible diag-The American Journal of Human Gnostic genetic finding (Table 4). This
variation also empowers creative
analysis at the individual sites, en-
riches data available to the working
groups, and provides opportunities
to move toward increasingly evi-
dence-based best practices for CGES.
The goal of the various CSER working
groups (Table 3) is to collaborate on
common issues that arise in different
ways across the sites to make collec-
tive recommendations. Many of therecommendations produced by these working groups
will ultimately influence issues that will affect the clinical
diagnostic yield of GCES. Although many of the individ-
ual studies have not yet completed their analyses, initial
results from individual studies and cross-cutting collabo-
rations are emerging, as highlighted below.Sequencing Specifications and Variant
Classification
Each U-award has developed and managed its own transla-
tional sequencing pipeline, including variant interpreta-
tion, that addresses the technical, analytic, and interpre-
tive components of the clinical sequencing process.2,26
The time between sample collection and the return of
the interpreted report at the start of the CSER consortium
projects was 16 weeks and is currently averaging about
13 weeks. Thus far, coverage of the sequenced target
(exome or genome) has averaged 203 or greater over
89%–98% of the exome or genome. Average depth of
coverage has ranged from 623 to 2333 for germline exome
sequencing, from 323 to 423 for germline genome
sequencing, and from 1663 to 2503 for tumor exome
sequencing. The Sequencing Standards working group is
exploring the genome and exome coverage across the
different platforms as defined by each site’s pipeline to
move toward a more comprehensive approach to clinical
sequencing. All results being returned to participants are
generated or confirmed in laboratories certified by the
Clinical Laboratory Improvement Amendments (CLIA).enetics 98, 1051–1066, June 2, 2016 1053
Table 1. CSER Consortium U-Awards
Project Name Institutionsa Project Goal Population Tissue Type Technique Disease Status Discloser of Results
BASIC3: Baylor Advancing
Sequencing into Childhood
Cancer Care
Baylor College of Medicine* incorporating CLIA-certified tumor
and blood exome sequencing
pediatric germline and
solid tumors
exome
sequencing
known disease oncologist with a genetic
counselor present for
consult if needed
CanSeq: The Use of Whole-Exome
Sequencing to Guide the Care of
Cancer Patients
Dana-Farber Cancer Institute,*
Broad Institute of MIT and
Harvard
improving cancer outcomes by
identifying biologically
consequential tumor alterations with
existing or emerging technologies
adult germline and
solid tumors
exome
sequencing
known disease oncologist with a referral
to genetic counseling if
needed
ClinSeq: A Large-Scale Sequencing
Clinical Research Pilot Study
National Human Genome
Research Institute*
comparing identified genetic variants
with individual and family-history
information
adult germline exome
sequencing
seemingly healthy genetic counselor and/or
medical geneticist
HudsonAlpha: Genomic Diagnosis
for Children with Developmental
Delay
HudsonAlpha Institute for
Biotechnology,* University of
Louisville
identifying genetic variations causing
developmental delay, intellectual
disability, and related phenotypes, as
well as medically relevant secondary
findings
adult and
pediatric
germline exome and
genome
sequencing
known disease medical geneticist and
genetic counselor
MedSeq: Integration of Whole
Genome Sequencing into Clinical
Medicine
Brigham and Women’s Hospital,*
Baylor College of Medicine,
Broad Institute of MIT and
Harvard, Duke University
integrating whole-genome
sequencing into clinical medicine in
healthy adults and adults with
cardiomyopathy
adult germline genome
sequencing
seemingly healthy
and known disease
primary-care physician or
cardiologist
MI-ONCOSEQ: Michigan Oncology
Sequencing Center
University of Michigan,* Johns
Hopkins University
implementing clinical sequencing for
sarcomas and other rare cancers
adult and
pediatric
germline and
solid tumors
genome
sequencing
known disease oncologist with a referral
to genetic counseling
NCGENES: North Carolina Clinical
Genomic Evaluation by Next-
Generation Exome Sequencing
University of North Carolina at
Chapel Hill*
investigating the use of whole-exome
sequencing in individuals with
hereditary cancer susceptibility,
genetic heart disorders, neurogenetic
disorders, and congenital
malformations
adult and
pediatric
germline exome
sequencing
known disease medical geneticist and
genetic counselor
NEXT Medicine: Clinical Sequencing
in Cancer: Clinical, Ethical, and
Technological Studies
University of Washington* studying the clinical implementation
of whole-exome sequencing in
participants with colorectal cancer or
polyposis
adult germline and
tumor
exome
sequencing
known disease genetic counselor and/or
medical geneticist
NextGen: Understanding the Impact
of Genome Sequencing For
Reproductive Decisions
Kaiser Permanente,* Oregon
Health & Sciences University,
Seattle Children’s Hospital,
University of Washington
integrating whole-genome
sequencing for preconception carrier
status and secondary findings into
clinical care
adult germline genome
sequencing
seemingly healthy genetic counselor
PediSeq: Applying Genomic
Sequencing in Pediatrics
Children’s Hospital of
Philadelphia,* University of
Pennsylvania
examining the use of whole-exome
and whole-genome sequencing in
five heterogeneous disease cohorts:
bilateral sensorineural hearing loss,
intellectual disability, nuclear-
encoded mitochondrial respiratory-
chain disorders, platelet-function
disorders, and sudden cardiac arrest
and/or death
adult and
pediatric
germline exome and
genome
sequencing
known disease genetic counselor and/or
medical geneticist,
cardiologist,
hematologist, neurologist
aAsterisks denote lead institutions.
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Table 2. CSER Consortium R-Awards
Project Name Institutionsa Project Goal
Challenges of Informed Consent
in Return of Data From Genomic
Research
Columbia University* developing a menu of approaches to deal with the challenges
of informed consent for genomic research
Disclosing Genomic Incidental
Findings in a Cancer BioBank:
An ELSI Experiment
Mayo Clinic,* University of
Minnesota, University of California,
San Francisco
determining how to manage return of results and secondary
findings to family members, including after the death of the
research participant
Impact of Return of Incidental
Genetic Test Results to Research
Participants in the Genomic Era
Columbia University* investigating preferences of participants enrolled in genomic
research about the disclosure of incidental genetic test results and
the psychosocial and behavioral impact of these disclosures
Innovative Approaches to Returning
Results in Exome and Genome
Sequencing Studies
Seattle Children’s Hospital* comparing traditional results-disclosure sessions (with a genetic
counselor and over the phone) with an innovative web-based tool
Presenting Diagnostic Results from
Large-Scale Clinical Mutation
Testing
Cleveland Clinic,* Mayo Clinic examining participant and professional understandings of
diagnostic results from large-scale clinical mutation testing and
attitudes toward testing
Return of Research Results From
Samples Obtained for Newborn
Screening
Johns Hopkins University* evaluating current existing state policies regarding the storage of
dried blood spots after newborn screening and associated research
use to develop policy recommendations
Returning Research Results in
Children: Parental Preferences
and Expert Oversight
Boston Children’s Hospital* exploring research-participant preferences in the return of
individual genomic research results and how this might be
incorporated into registry and/or biobank research structure
Returning Research Results of
Pediatric Genomic Research to
Participants
Vanderbilt University,* McGill
University, Baylor College of
Medicine, University of Chicago
exploring legal issues raised by the return of genomic research
results in minors
The Presumptive Case Again
Returning Individuals Results in
BioBanking Research
Children’s Mercy Hospital* analyzing claims that the return of bio-repository results is morally
obligatory or permissible in genomic research
aAsterisks denote lead institutions.The CSER consortium has worked to improve partici-
pant care by exploring variant assessment26,27 and by
comparing approaches across the sites. Early efforts in
CSER sites9 helped to inform the working group of the
American College of Medical Genetics and Genomics
(ACMG) and Association for Molecular Pathology (AMP)
in developing current annotation guidelines.28 To eval-
uate whether the published ACMG-AMP guidelines
improve the consistency of variant classification across
sites, a second exercise has focused on intra- and inter-
laboratory differences by applying laboratory-specific
and ACMG-AMP variant-classification criteria for 99
germline variants. Variant classification based on the
ACMG-AMP guidelines was concordant with each site’s
prior laboratory-specific variant classifications 79% of
the time (intra-laboratory comparison); however, only
34% of the variant classifications were concordant in in-
ter-laboratory classifications (see Amendola et al.29 in this
issue of the American Journal of Human Genetics). For the
inter-laboratory comparison, it made no difference
whether the laboratories used their own prior criteria or
the ACMG-AMP guidelines, suggesting subjectivity in
the application of the ACMG-AMP guidelines; however,
the guidelines were useful in providing a common frame-
work for facilitating resolution of differences between
sites. After consensus efforts, 70% concordance was
achieved, and only 5% of variants had differences thatThe Americmight affect clinical care. These findings will contribute
to future iterations in current ACMG-AMP guidelines
and improve and standardize the classification of variant
pathogenicity.
Comparison of sequenced variants classified as patho-
genic and likely pathogenic by the different U-award
sites is instructive, especially in light of the different
sets of genes and variant-classification levels that each
site selected in reporting their secondary findings. For
example, some sites used only small and focused sets of
genes that met actionability criteria in advance of
sequencing, whereas other sites started with broader lists
of thousands of genes and then reviewed the gene-level
information alongside the variant-level information
when a potentially pathogenic variant or novel loss-of-
function variant was identified in the gene. As a result,
among participants sequenced across the CSER con-
sortium, comparisons of the rate of secondary findings
at each site are difficult.10 Similarly, the decision to
return any pharmacogenomic information or recessive
carrier status also varied across sites by design (e.g., one
site focused exclusively on the latter). As of the latest re-
ported individual-level data, 3,296 participants have
been sequenced and have received their sequencing
results. Among sites disclosing any pharmacogenomic in-
formation (n ¼ 4), 32.3%–100% of sequenced partici-
pants received information about one or more variant(s)an Journal of Human Genetics 98, 1051–1066, June 2, 2016 1055
Table 3. Cross-Consortium Collaborative Working Groups
Group Name Project Goal Significant Findings Working-Group References
Actionability and
Return of Results
(Act-ROR)
defining the principles and processes guiding the definition of
‘‘actionable gene’’ across the consortium, including outcomes and
discrepancies; developing variant-classification consensus;
developing best practices for analysis and communication of
genomic results
defining an ‘‘actionable’’ gene by developing consensus regarding
variant classification and developing decision support resources
around actionability; developing guidance for classification of
secondary findings
Amendola et al.,9 Berg et al.,10
Jarvik et al.11
Electronic Health Records understanding and facilitating collaboration related to the
integration of genomic information into the EHR, decision support,
and linkage to variant and knowledge databases
understanding and facilitating cross-site collaboration, EHR
integration, decision support, and database linkage; analyzing the
current state of the EHR among six CSER sites, as well as presenting
genetic data within the EHR among eight sites; ascertaining current
display of genetic information in EHRs; defining priorities for
improvement
Shirts et al.,12 Tarczy-Hornoch
et al.13
Genetic Counseling investigating current genetic-counseling topics related to whole-
exome and -genome sequencing, including but not limited to
recruitment and enrollment, obtaining informed consent,
returning sequencing results, and interacting with participants and
families in both research and clinical settings
analyzing CGES topics related to genetic counseling, including
informed-consent best practices and lessons learned from returning
results
Tomlinson et al.,14 Bernhardt
et al.,15 Amendola et al.16
Informed Consent and
Governance
discussing emerging issues and developing new and creative
approaches related to informed consent in the sequencing context;
developing standardized consent language; analyzing experience
with institutional governance of genomic data
analyzing CSER approaches to informed consent for the return of
genomic research data; supporting the development of new and
creative approaches to consent, including best practices and
standardized language and protocols; compiling CSER experiences
with institutional governance of genomic data
Henderson et al.,17
Appelbaum et al.,18 Koenig19
Outcomes and Measures identifying priority areas for investigating psychosocial, behavioral,
and economic outcomes related to genome sequencing;
coordinating measurement of key outcomes across CSER sites;
identifying research strategies to generate evidence to inform
health-care policies
examining participant outcomes to inform conversations regarding
the efficacy and harms of sequencing, as well as the costs and
impacts of genomic sequencing on the health-care system
Gray et al.20
Practitioner Education exploring the growing need for medical genetics education
materials for health-care practitioners
newly formed workgroup aimed at exploring the unique
educational needs of health-care providers; currently compiling and
assessing available resources and looking for gaps and avenues for
using expertise and shared experiences within CSER to aid in
practitioner genomic education and application
–
Pediatrics exploring and attempting to develop standardized approaches to
address the unique ethical, legal, and practical challenges related to
returning results in studies involving pediatric populations
deeply analyzing the issues related to childhood genomic
sequencing, including comparing current guidelines and
examining ethical responsibilities and recommendations for a
future framework for genomic sequencing in children
Clayton et al.,21 Brothers
et al.22 McCullough et al.23
Sequencing Standards developing and sharing technical standards for sequencing in the
clinical context; developing best practices for genomic sequencing
and variant validation
analyzing clinically relevant genomic regions that are poorly
covered in CGES across ten CSER sites to learn more about target
areas for future improvement; developing tools and processes to
allow standardized analyses of poorly covered regions at other
clinical sequencing centers
–
Tumor exploring the unique technical, interpretive, and ethical challenges
involved in sequencing somatic cancer genomes
educating the oncology community regarding the spectrum of
potential tumor sequencing results, as well as secondary findings
from germline sequencing and revelations of true germline findings
from tumor sequencing
Parsons et al.,24 Raymond
et al.25
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Figure 2. Cumulative Enrollment and Sequencing of Participants in the CSER U-Awards
These numbers reflect participant enrollment (including physician enrollment at some sites). Several sites (MedSeq, CanSeq, and
NextMed) enrolled control participants (who were not sequenced) in a randomized trial.related to pharmacogenomic response. 2%–92% of par-
ticipants have received information about recessive car-
rier variants, and this wide range is due to differences
in the number of genes considered for return at each
site. When just the genes recommended by the ACMG
for secondary result return were examined,30 68 of the
3,296 (2.1%) CSER research participants were reported
to have a pathogenic or likely pathogenic variant in at
least one of these genes unrelated to the primary test
indication; site-specific percentages varied from 0.28%
to 6.52%. This variation can be attributed to a variety
of factors, including differences in variant-classification
methods,29 small sample sizes at many of the sites, and
the fact that some sites report only pathogenic findings,
whereas others report pathogenic and likely pathogenic
findings and even variants of uncertain significance.
Also, some sites report only on a subset of the 56
ACMG genes, such as genes associated with cancer
predisposition.
The variant-interpretation project described above is
now helping to bring more consistency to the variant-clas-
sification process across sites. In addition, the CSER con-
sortium is working with sites to submit all of their classified
variants to ClinVar to improve variant-classification com-
parisons with other submitters and identify differences
that can be resolved. As of the latest reporting, over
2,795 classified variants have been submitted to ClinVar
by the CSER sites, making CSER one of the top 20 submit-
ters to ClinVar. Additionally, individual-level datasets
containing genotypes and phenotypes from over 2,401 in-
dividual-level datasets have been submitted to dbGaP.The AmericImplementation of Clinical Sequencing in the
CSER Consortium
Among the four CSER sites conducting sequencing in
cancer participants, the BASIC3 trial has presented prelim-
inary data showing that nearly 40% of pediatric partici-
pants with solid tumors have potentially actionable
mutations when the results of tumor and germline exome
sequencing are combined.31 CanSeq has focused on
enrolling participants with advanced colorectal and lung
cancer, of whom 88.4% were found to have actionable
or potentially actionable somatic genome alterations,
whereas the Michigan Oncology Sequencing Center (MI-
ONCOSEQ) has identified clinically relevant results from
tumor sequencing in 60% of adult and pediatric cancer
participants.32 Both the CanSeq and MI-ONCOSEQ
projects have implemented production-scale exome
sequencing from archival tissue samples, and the latter
program is pioneering an exome-capture transcriptome
protocol that improves performance on degraded RNA.33
The NEXT Medicine study has incorporated exome germ-
line sequencing through a randomized trial to examine
care outcomes in participants with hereditary colorectal
cancer and/or polyps.34
CGES has also been utilized in the diagnosis of
numerous suspected genetic conditions. For six disease co-
horts that have undergone exome sequencing in PediSeq,
the diagnostic rates have varied from 6% in platelet disor-
ders to 20% in sudden cardiac death to 50% in intellectual
disability.35 PediSeq has also created phenotype and pedi-
gree capture technologies, including the use of phenotypesan Journal of Human Genetics 98, 1051–1066, June 2, 2016 1057
Table 4. Yield of Variants Related to Phenotypes in Sequenced Symptomatic U-Award Participants
Clinical Characteristics Sample Sizea
Percentage of Participants with at Least One Finding
(Median No. of Variants Reported)
P or LP VUS Single Recessiveb Other
Germline cancer (all) 1,142 6.2%(1) 36% (1) 2.4% (1) 0.4% (1)
Syndromic ID or autism 431 19% (1) 13% (1) 0.7% (1) 1.2% (2)
Other DD and ID 50 28% (1) 28% (2) 14% (1) 0%
Cardiomyopathy 104 27% (1) 28% (1) 0% 1.0% (1)
Other cardiovascular 274 5% (1) 11% (2) 0% 0.4% (1)
Ophthalmology 80 39% (1) 16% (1) 7.5% (1) 0%
All other characteristics 137 18% (1) 28% (1) 19% (1.5) 2.2% (1)
Abbreviations are as follows: DD, developmental delay; ID, intellectual disability; P, pathogenic; LP, likely pathogenic; and VUS, variant of uncertain significance.
aThis table does not account for 1,863 healthy individuals within CSER.
bIndividuals with a single recessive mutation in a gene related to the described phenotype.to prioritize gene interpretation36 and the pedigree-draw-
ing program Proband, an app with over 1,700 downloads
to date. NCGENES and the HudsonAlpha sites both enroll
children with intellectual disabilities and have both
observed similar variations in diagnostic rates. NCGENES
includes participants with a broad range of diseases; diag-
nostic rates range from 21% in familial cancer to 39%
in children with dysmorphic features to 58% among indi-
viduals with retinopathy.37 The MedSeq project, one of
three randomized trials within the CSER consortium, is
exploring the potential advantages of whole-genome
sequencing (WGS) in participants with cardiomyopathy
and has found that WGS robustly confirms diagnoses pre-
viously made by next-generation cardiomyopathy panels
and occasionally identifies previously undetected etiologic
candidates in participants who were not diagnosed by
panel testing.38
In an attempt to quantify the importance of secondary
findings, the NCGENES site created a semiquantitative
‘‘binning’’ metric39,40 (versions of which have been
broadly adapted by other efforts).41,42 NCGENES reports
the frequency of discovering a medically actionable sec-
ondary finding to be 3.4%. NEXT Medicine, in conjunc-
tion with the Actionability and Return of Results working
group,10 defined a large list of genes for medically action-
able conditions and estimated that 0.8% of individuals of
European ancestry and 0.5% of individuals of African-
American ancestry would be expected to have a patho-
genic variant returned as an incidental finding from exome
sequencing.9 PediSeq reviews variants in a list of nearly
3,000 genes and returns secondary findings for risk of
Mendelian disease in 10%–15% of participants and carrier
findings in nearly 90% of participants. The MedSeq project
worked collaboratively with Clinical Genome Resource
(ClinGen)26,41 to apply a method for gene-disease validity
classification to evaluate which of the approximately 4,500
disease-associated genes analyzed to date have sufficiently
strong evidence for returning variants. The BASIC3 study
utilizes the ACMG list of 56 genes plus additional action-1058 The American Journal of Human Genetics 98, 1051–1066, Juneable genes evaluated by the project 2 team and has an over-
all secondary-findings rate of 4.8%.2
Although secondary findings in the context of diag-
nostic sequencing represent a kind of ‘‘opportunistic
screening,’’3,43,44 several sites have explored the use of
sequencing in persons without a suspected genetic condi-
tion, a model closer to actual population screening.
ClinSeq, the NHGRI intramural program, has treated
non-diagnostic sequencing as a hypothesis-generating
methodology to report on the implications of secondary
findings associated with heart disease,45 malignant hyper-
thermia,46 diabetes,47 a form of arrhythmia,48 and the
discovery of a late-onset neurometabolic disorder.49 After
identifying loss-of-function variants in genes for which
haploinsufficiency is associated with disease, ClinSeq in-
vestigators followed up with in-depth phenotyping to
reveal that roughly half of the population carrying such
variants had subtle phenotypes of underlying genetic dis-
ease but were unaware of this.50 Similarly, the MedSeq
project has returned pathogenic variants, likely patho-
genic variants, and even suspicious variants of uncertain
significance in healthy middle-aged adult volunteers to
their primary-care physicians and cardiologists by using a
single-page summary of whole-genome results.26,51 This
report categorizes risk variants for monogenic diseases (in
genes associated with dominant disease or in genes associ-
ated with autosomal recessive disease and in which bial-
lelic pathogenic and likely pathogenic variants have been
identified), recessive carrier variants, pharmacogenomic
variants, SNP-based risk scores for common cardiovascular
conditions, and variants that characterize red blood cell
and platelet antigens.26,38,51–53 BASIC3 and CanSeq are
enrolling large teams of pediatric and adult oncologists
who receive exome sequencing results and disclose them
to families of pediatric cancer participants and adult cancer
participants. The primary-care physicians in MedSeq and
the oncologists in CanSeq do not have formal genetics
training, but in the case of MedSeq, they have been given
a brief training module to assist them in interpreting and2, 2016
acting on the genome reports.38,51 In MedSeq, both pro-
viders and sequenced participants (along with control in-
dividuals who are not sequenced) are studied through
surveys, interviews, and close monitoring of electronic
health records (EHRs), yielding insights about physician
preparedness for CGES.54–57
Several U-award sites are returning carrier status in
addition to monogenic secondary findings. For example,
both the MedSeq project and the NCGENES study
include carrier results as additional findings in adult
participants. The NextGen study is a randomized trial
directly investigating the implementation of carrier
screening to aid reproductive decision making in adults
not known to be a carrier of genetic disease. Focus
groups exploring participant and clinician perspectives
have shown that potential participants have differing
degrees of interest in learning their carrier status,58 and
of those enrolled so far, 71% have at least one carrier
result, and 89% of participants are choosing to receive
results in one of four optional categories (serious, moder-
ate, adult-onset, and unpredictable). The ClinSeq study
is also conducting a randomized trial comparing the re-
turn of carrier results through standard-of-care coun-
seling and that through a web site to assess the impact
of counseling approach on the cost of genomic health
care.Outcomes and ELSI Issues in Clinical Sequencing
The main results from many of the projects have not yet
been analyzed or published because enrollment is still
ongoing for some of the projects. However, the CSER con-
sortium is already providing insights into medical, behav-
ioral, psychosocial, and economic outcomes related to the
growing use of genomic data in the clinic.20,59,60 The con-
sortium’s Outcomes andMeasures working group has iden-
tified common research priorities, developed instruments
to facilitate data harmonization, and initiated cross-site
aggregate and comparative analyses.20 The inclusion of in-
vestigators with expertise in normative and legal ELSI ana-
lyses provides additional assurance that best practices
based upon CSER data will not only be based on evidence
but also be ethically and legally sound.
A major focus to date has been the disclosure of second-
ary genomic findings to participants. Early findings, based
on qualitative, quantitative, and mixed-methods research,
suggest that participants and research participants queried
during the informed-consent process are usually receptive
to learning such findings but that preferences are influ-
enced by the precise nature of the findings, how the offer
is made, and a number of individual participant attri-
butes.59,61–67 For example, in the NCGENES study, adult
participants are randomized to either a ‘‘control’’ group
or a ‘‘decision’’ group, participants in the latter of which
are asked to decide whether they wish to receive any of
the six categories of non-actionable secondary findings.The AmericWhereas the majority in the ‘‘decision’’ group initially
stated an intention to request all secondary findings, fewer
than one-third actually requested one or more, demon-
strating a difference between hypothetical and real-world
actions.
The CSER consortium’s empirical studies of clinicians’
and genomic researchers’ attitudes about disclosing second-
ary genomic findings show that although few have signifi-
cant experience in returning such findings, most report
that they are motivated to do so in at least some circum-
stances.55,68–70 At the same time, CSER studies highlight
the many complexities, both normative and practical,
that invariably enter into decisions about whether, when,
and how such findings should be made available.43,69,71–77
The CSER consortium has also addressed the challenges
involved in obtaining informed consent for clinical
sequencing, including tailoring approaches that are best
suited to specific clinical contexts. The consortium has
published an empirical analysis of the consent forms
used at six U-award sites and three R-award sites, along
with recommendations for ways in which consent forms
can be improved.17 CSER investigators have defined four
models of consent for the disclosure of secondary find-
ings,18 identified seven discrete challenges representing
gaps in genome sequencing knowledge and faced by ge-
netic counselors,78 and provided illustrative case examples
of practical issues involved in consent and disclosure
decisions,79,80 all suggesting an expanded future role for
genetic counselors.14–16,81,82
Through its Pediatrics working group, CSER has focused
considerable attention on genomic sequencing in chil-
dren.21–23 Several site-specific publications have addressed
the appropriate role of children in decision making,83–85
preferences of genetic professionals regarding the disclo-
sure of findings in pediatrics,68,70,86 limitations in parents’
understanding of choices regarding receipt of their chil-
dren’s findings,87 and certain unique features of informed
consent in pediatric oncology.79
CSER investigators have also conducted important legal
and regulatory analyses relevant to clinical sequencing,
including the legal liability for disclosure or non-disclosure
of findings to patients, research participants, and family
members.88–91 Other topics include the legal implications
of incorporating genomic data into EHRs,92,93 the limita-
tions of current laws and the potential impact of recent
changes to federal privacy and laboratory regulations on
access to one’s genetic data,94,95 and a comparison of US
law and policy and that of other countries on family access
to a proband’s genomic findings.96
Finally, early research has assessed the economic value
and cost-effectiveness of returning secondary find-
ings,97,98 and additional efforts are underway. CSER inves-
tigators have highlighted the need for future research in
behavioral economics by recognizing that provision of
information does not necessarily lead to health benefits.
This research will provide insights into participants’
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downstream impacts on the utilization of health services,
both positive and negative, providing strategies for maxi-
mizing positive uses of genomic information.99,100Additional Dissemination and Outreach Activities
The CSER consortium has established a shared, real-time
community of research sites pursuing common goals in
related yet distinct settings. Thus, the value of the con-
sortiumgoesbeyond the individualpublicationsmentioned
above. When CSER was initially funded in 2011, each site
was challenged to implement clinical sequencing, stan-
dardize variant interpretation, reduce sequencing turn-
around time, and develop reliable bioinformatics pipelines.
Addressing these common challenges among sites has
yielded insights that, when synthesized, are becoming rele-
vant to the broader scientific community. For example, sites
have adopted different approaches to the analysis of clinical
sequencing data, best exemplified by the ‘‘diagnostic-gene-
list’’ approachemployedbysomesites andthe ‘‘variant-first’’
approach adopted by others. An ability to compare such
analytical approaches continues to inform the entire field
in its ongoingefforts tooptimize interpretation.Moregener-
ally, there have been vibrant discussions and sharing of ap-
proaches to informed consent, educational materials, and
disclosure methods across many CSER sites. More recently,
working groupshave been exploring approaches to improve
sequencing standards, coverage of clinically relevant genes,
andvariant annotationbyusingexistingandnewlyadopted
ACMG variant-classification guidelines. Looking ahead,
CSER will continue to address questions that are best
answered across multiple sites and in multiple settings. For
example, projects related to the return of carrier status,
re-interpretation of results, management of secondary
findings, ethical approaches to combining research with
clinical care, and downstream costs of genomic testing are
underway.
CSER-related interactions often expand to related
genome sequencing efforts. For example, CSER investiga-
tors are interacting or collaborating with other consortia
in the areas of EHR-based phenotyping, genotyping, and
integration of results into the EHR (Electronic Medical Re-
cords and Genomics [eMERGE]);101–103 community-based
curation of genes and variants (ClinGen);41 undiagnosed
diseases (Undiagnosed Disease Network [UDN]); imple-
mentation of genomic testing in diverse settings (Imple-
menting Genomics in Practice [IGNITE]); newborn
sequencing (Newborn Sequencing in Genomic Medicine
and Public Health [NSIGHT]); ethics (Centers for Excel-
lence in ELSI Research [CEERs]); prostate cancer (Stand
Up 2 Cancer [SU2C] and Prostate Cancer Foundation
[PCF] international dream team); trials of prospective pre-
cision medicine in cancer (National Cancer Institute and
Children’s Oncology Group Pediatric MATCH study);104
and the evolving role of the clinical geneticist (Clinical Ge-
netics Think Tank). These inter-consortium interactions1060 The American Journal of Human Genetics 98, 1051–1066, Junevary in nature from informal consultations to resource
sharing to joint meetings and publications.11,12,22,105
CSER is also informing the development of professional
guidelines28,30,106,107 by sharing resources (e.g., gene lists)
and serving as a ‘‘sandbox’’ in which early implementation
can be assessed. Other dissemination activities include the
release of open-source software,108 deposition of data into
ClinVar and dbGaP, and being a part of high-profile ses-
sions at national medical and bioethics meetings. Study-
specific resources such as consent forms, study protocols,
educational materials, and sample reports are made pub-
licly available at the CSER Coordinating Center’s website
(see Web Resources for links to these groups).
Efforts to facilitate outreach to individuals and commu-
nities outside academic medical centers have also been im-
plemented. By initiating collaborations with rural and
underserved populations, some sites are establishing
broader availability of genome sequencing, extending its
clinical reach outside of academia and facilitating robust
participation by underserved minority groups. Sites inter-
acting with state government agencies that serve families
of special-needs children or comprising integrated delivery
systems are using their CSER experience as a platform to
educate the public and stakeholders who make coverage
decisions.Future Directions for the CSER Consortium
Through its combination of individual scientific enter-
prise, practitioner participation, and collective synergy,
the CSER consortium is uniquely poised to fill some of
the most important evidence gaps in the implementation
of genomic medicine. Looking toward a future with
widespread evidence-based and equitable availability of
genomic medicine, there are critical challenges in terms
of implementing technical refinements, including accessi-
bility to individuals of diverse ethnic and socioeconomic
backgrounds and the attainment and demonstration of
desired medical outcomes. In particular, CSER sites can
be expected to further advance analyses of observed differ-
ences in variant interpretation in concert with ClinGen41
and to identify new approaches for calling structural vari-
ation from next-generation sequencing data. Finally, the
genomics regulatory arena is very dynamic with evolving
FDA oversight109,110 and proposed changes to the Com-
mon Rule. The CSER consortium has and will continue
to play an important role in evaluating and communi-
cating the impact of this rapidly evolving area in topics
such as consent and disclosure.
The CSER consortium, along with all genomics investi-
gators, must also consider whether and how genomic
medicine might exacerbate disparities in health and
health-services utilization to ensure that the intended
benefits of genomic medicine are justly distributed.111
There are several reasons why poor, rural, and racial and
ethnic minority populations might be less likely to realize2, 2016
tangible health-related benefits as genomic medicine be-
comes more commonplace. Existing databases of dis-
ease-associated genes and variants are overwhelmingly
drawn from individuals of European ancestry, and popula-
tions of non-European ancestry have patterns of genetic
variation that are not yet well characterized in control
populations. This lack of data complicates the interpreta-
tion of novel and rare variants. Also, historical and
continuing social disparities in health-care access,
health-insurance coverage, and community engagement
and trust are heightened by issues raised in genomics.
Without concerted intervention, these converging forces
threaten to perpetuate and expand current health dispar-
ities in ways that might disadvantage members of racially
and ethnically diverse communities for decades. A num-
ber of sites within the CSER consortium have begun ex-
panding their enrollment of minority ethnicities to begin
addressing these inequalities and will continue to identify
relevant opportunities.
More formal studies in comparative effectiveness and
cost-effectiveness are necessary for answering questions
about whether and under what circumstances sequencing
should be applied and for guiding third-party payment
for clinically helpful genomic services. The degree to which
the identificationof secondaryfindings and the sequencing
of asymptomatic individuals might lead to downstream
health benefits and incur or offset downstream costs will
be critical. Deeper phenotyping of apparently pathogenic
variants in participants who do not show symptoms of an
associated genetic condition will be required and will pro-
vide key information on the classification of variant patho-
genicity, penetrance estimation, and the identification of
modifying or protective factors that could provide impor-
tant insights into future treatment of rare or even common
conditions. Butwith iterative andmore in-depthphenotyp-
ing and the use of tools ranging from wearable monitoring
devices to microscopic processes in cell culture, there is an
opportunity to define disease and diminished function
in entirely new ways. As medicine enters an era where
sequencing and other -omics can be applied routinely, the
CSER consortium is helping to accelerate the realization
of preventive and precision medicine.Supplemental Data
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